aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded as a clinical-stage, privately held medtech company, Presidio Medical is dedicated to developing a transformational neuromodulation platform aimed at treating diseases caused by undesired neural activity. Their core mission is to provide innovative remedies for disorders affecting neuronal activity, thereby improving patient outcomes and quality of life. The company's primary product leverages ultra-low frequency current waveforms to reversibly block axonal conduction and manage chronic pain, positioning them at the forefront of neuromodulation therapies.
Notable affiliated individuals include Martyn G. Jones, Evan Rogers, and James P. Harris, who have contributed to significant scientific publications in the field. Presidio Medical has achieved key milestones in clinical trials, demonstrating the efficacy of their neuromodulation platform in managing chronic pain. Their impact is marked by advancing the treatment landscape for neural disorders, offering new hope for patients with conditions previously deemed difficult to manage.
Operating Status
Active
Main Product(s)
Medical Devices
Technology
Neuromodulation
Tags
Healthtech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Presidio Medical founded?
Presidio Medical was founded in 2017.
Where is Presidio Medical's headquarters located?
Presidio Medical's headquarters is located in South San Francisco, CA, US.
When was Presidio Medical's last funding round?
Presidio Medical's most recent funding round was for $72M (USD) in June 2023.
How many employees does Presidio Medical have?
Presidio Medical has 59 employees as of Feb 4, 2024.
How much has Presidio Medical raised to-date?
As of July 05, 2023, Presidio Medical has raised a total of $102M (USD) since Jun 26, 2023.
Add Comparison
Total Raised to Date
$102M
USD
Last Update Jun 26, 2023
Last Deal Details
$72M
USD
Jun 26, 2023
Series C
Total Employees Over Time
59
As of Feb 2024
Presidio Medical Address
395 Oyster Point Blvd
suite 550
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts